Empirical therapy advisor

Before culture results are back: how likely is each antibiotic to cover the pathogen of a patient like this one, in this ward, given the last 12 months of results and today's alerts.

Patient

More options · any onset · target 80 % · 2025-02-02
Based on 1235 first isolates · PHC-S · Cystitis (lower UTI) · 2024-02-04 → 2025-02-02
Health centre South
Per-organism detail: PHC-S urine resistance view →
Narrowest option reaching 80 % coverage, no active warning
nitrofurantoin 83 % (81 %–85 %)
No tissue or blood levels: cystitis only.
Not covered: Proteus mirabilis (8 %), Pseudomonas aeruginosa (4 %), Klebsiella pneumoniae (4 %)
AntibioticCoverage, 12 months (95 % CI)12 mo4 wk
nitrofurantoin NIT
trend · Escherichia coli lower UTI only
83 %
81 %
n = 86
meropenem MEM
trend · Escherichia coli reserve
82 %
83 %
n = 86
piperacillin-tazobactam TZP
trend · Escherichia coli broad spectrum
78 %
81 %
n = 86
ciprofloxacin CIP
trend · Escherichia coli
77 %
79 %
n = 86
mecillinam MEC
trend · Escherichia coli lower UTI only
76 %
79 %
n = 86
trimethoprim TMP
trend · Escherichia coli lower UTI only
75 %
77 %
n = 86
ceftriaxone CRO
trend · Escherichia coli
74 %
78 %
n = 86
70 %
71 %
n = 86
51 %
55 %
n = 86
vancomycin VAN
trend · Enterococcus faecalis Gram-positive only
15 %
17 %
n = 86
clindamycin CLI
trend · Staphylococcus aureus Gram-positive only
4 %
8 %
n = 86
4 %
3 %
n = 86

Most likely organisms for this profile

Escherichia coli
51 %
Klebsiella pneumoniae
13 %
Enterococcus faecalis
10 %
Proteus mirabilis
8 %
Staphylococcus aureus
4 %
Pseudomonas aeruginosa
4 %

Decision support only: coverage is the share of first isolates from similar patients that were susceptible (an organism not tested for a drug counts as not covered). It does not replace local treatment guidelines, allergy and severity assessment, or clinical judgement. The black tick on each bar is the coverage target; the bracket is the 95 % confidence interval.

AEI · Tyks Laboratoriot × Mylab · JunctionX Turku. Synteettinen aineisto; EARS-Net-luvut: ECDC.